16/11/2017 - 08:30 StockMarketWire
HSBC today reaffirms its reduce investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 4380p (f...
15/11/2017 - 09:35 StockMarketWire
AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the US Food and D...
15/11/2017 - 07:00 RNS
RNS Number: 5114W AstraZeneca PLC 14 November 2017 This announcement contains inside information 14 November 2017 22:45 GMT FASENRA (BENRALIZUMAB) RECEIVES US FDA APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA Fasenra distinctively targets and rapidly depletes eosinophils and is the first respiratory biologic with an 8-week maint...
10/11/2017 - 13:06 StockMarketWire
AstraZeneca has confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicin...
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment